Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.84 |
| ▸ | JAK1 | P23458 | 12/20 | 0.84 |
| ▸ | TYK2 | P29597 | 1/20 | 0.84 |
| ▸ | AXL | P30530 | 1/20 | 0.84 |
| ▸ | JAK3 | P52333 | 1/20 | 0.84 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.84 |
| ▸ | MERTK | Q12866 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itacitinib SCHEMBL2396080 | 0.91 | JAK2 (1.00) | JAK2JAK1TYK2AXLJAK3 | |
| Itacitinib SCHEMBL29360482 | 0.91 | JAK2 (1.00) | JAK2JAK1TYK2AXLJAK3 | |
| Itacitinib SCHEMBL29377548 | 0.91 | JAK2 (1.00) | JAK2JAK1TYK2AXLJAK3 | |
| Itacitinib SCHEMBL29456952 | 0.91 | JAK2 (1.00) | JAK2JAK1TYK2AXLJAK3 | |
| SCHEMBL2396847 | 0.90 | JAK2 (1.00) | JAK2JAK1TYK2AXLJAK3 | |
| SCHEMBL29422091 | 0.90 | JAK2 (1.00) | JAK2JAK1TYK2AXLJAK3 | |
| SCHEMBL2398710 | 0.90 | JAK2 (0.90) | JAK2JAK1TYK2AXLJAK3 | |
| SCHEMBL2392525 | 0.88 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL29422106 | 0.88 | JAK2 (1.00) | JAK2JAK1 | |
| SCHEMBL2396930 | 0.88 | JAK2 (1.00) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
| WO-2017079519-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20160347734-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150183805-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183805-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 6/4885 |
| US-20160347734-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.